Recommendations for special populations: The treatment of hypertension in diabetes mellitus

Endocrinologist

Volumn 14, Issue 6, 2004, Pages 368-381

  Tan, Anjanette S ^a   Kuppuswamy, Saravanan ^a   Whaley Connell, Adam T ^a   Kurukulasuriya, L Romayne ^a   Sowers, James R ^a,b,c,d  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Univ of MO Health Sciences Center ^*  (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cardiovascular disease; Diabetes mellitus; Endothilial dysfunction; Hypertension; Insulin resistance; Metabolic syndrome; Microabuminuria; Renin angiotensin aldosterone system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; PRAZOSIN; RAMIPRIL; ROSIGLITAZONE; THIAZIDE DIURETIC AGENT; VALSARTAN; VASODILATOR AGENT;

AFRICAN AMERICAN; AMERICAN INDIAN; ANTIHYPERTENSIVE ACTIVITY; ASIAN AMERICAN; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIABETIC NEUROPATHY; DIET THERAPY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG PREFERENCE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; DYSAUTONOMIA; ELDERLY CARE; ELECTROLYTE DISTURBANCE; ENDOTHELIUM INJURY; ETHNIC GROUP; EXTRACELLULAR SPACE; HEADACHE; HEALTH BEHAVIOR; HISPANIC; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY ARTERY STENOSIS; LIFESTYLE; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC DISORDER; MICROALBUMINURIA; MUSCLE WEAKNESS; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT CARE; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; POPULATION; PROTEINURIA; PULSE RATE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BALANCE; SYNCOPE; SYSTOLIC BLOOD PRESSURE;

EID: 9144236380     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000146262.10013.e7     Document Type: Review

References (170)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2003. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003. Available at: www.cdc.gov/diabetes/pubs/factsheet. htm. Accessed November 30, 2003.
2. National Center for Health Statistics. Healthy People 2010, Diabetes Progress Review. Available at: http://www.cdc.gov/nchs/hphome.htm. Accessed December 18, 2002.
3. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Advance Data. 2002;328:1-32.
4. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension. 1995;26:869-879.
5. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
7. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:S5-S10.
8. Schunkert H. Obesity and target organ damage: the heart. Int J Obesity. 2002;4(suppl):S15-S20.
9. Sowers JR, Khoury S. Diabetes and hypertension: a review. Primary Care. 1991;18:509-525.
10. Henry P, Thomas F, Benetos A, et al. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypertension. 2002;40:458-463.
11. Mcfarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713-718.
12. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
13. De Fronzo RA. The triumvirate beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667-687.
14. Edelson GW, Sowers JR. Treatment of hypertension in selected patient groups: an emphasis on diabetes mellitus and hypertension. Endocrinologist. 1994;4:205-211.
15. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens. 1995;13:1457-1462.
16. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000;342:969-970.
17. Facchini F, Chen Y-DI, Clinkingbeard C, et al. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens. 1992;5:694-699.
18. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-382.
19. Sawicki PT, Heinemann L, Starke A, et al. Hyperinsulinaemia is not linked with blood pressure evaluation in patients with insulinoma. Diabetologia. 1992;35:649-652.
20. Heise T, Magnusson K, Heinemann L, et al. Insulin resistance and the effect of insulin on blood pressure in essential hypertension. Hypertension. 1998;32:243-248.
21. Epstein M, Sowers JR. Insulin resistance in hypertension - a focused review. Am J Med Sci. 1993;306:345-347.
22. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14: 173-194.
23. Anderson EA, Hoffman RP, Balon TW, et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
24. Berne C, Fagius J, Pollare T, et al. The sympathetic response to euglycaemic hyperinsulinaemia. Diabetologia. 1992;35:873-879.
25. Sowers JR. Insulin resistance and hypertension. Mol Cell Endocrinol. 1990;74:C87-C89.
26. Duncan BB, Schmidt MI, Pankow JS, et al. Low-grade systemic inflammation and the development of diabetes: the Atherosclerosis Risk in Communities Study. Diabetes. 2003;52:1799-1805.
27. Weisberg SP, McCann D, Desnai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112: 1796-1808.
28. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
29. Abdel-Wahab N, Weston BS, Roberts T, et al. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol. 2002;13:2437-2445.
30. Vlassara H. Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med. 1994;124:19-30.
31. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.
32. Bakris G, Palant CE, Walsh MF, et al. Analogy between endothelial and mesangial cells. In: Sowers JR, ed. Endocrinology of the Vasculature. Totowa, NJ: Humana Press; 1996:341-355.
33. McFarlane SI, Sowers JR. Aldosterone function in diabetes mellitus: Effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003;88:516-523.
34. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597-H1602.
35. Sechi LA, Melis A, Tedde R. Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism. 1992;4:1261-1226.
36. American Diabetes Asssociation. Nephropathy in diabetes: clinical practice recommendations. Diabetes Care. 2004;27(suppl 1):S79-S83.
37. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of Chronic Kidney Disease: a position statement of the National Kidney Foundation (NKF) and the national institute of Diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003;42:617-622.
38. Dineen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
39. Bakris GL. Microalbuminuria: prognosticator implications. Curr Opin Nephrol Hypertens. 1996;5:219-223.
40. Bakris GL, Walsh MF, Sowers JR. Endothelium/mesangium interactions: role of insulin-like growth factors. In: Sowers JR, ed. Endocrinology of the Vasculature. Totowa, NJ: Humana; 1996:341-356.
41. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens. 2003;16:41S-45S.
42. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35-43.
43. Sowers JR, Haffher S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension. 2002;40:781-788.
44. Ljungman S, Wikstrand J, Hartford M, et al. Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective 10 year follow-up of middle-aged non-diabetic normal and hypertensive men. Am J Hypertens. 1996;9:770-778.
45. K/DOQ1 clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39:S1-246.
46. Arun CS, Stoddart J, Mackin P, et al. Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care. 2003;26:2144-2149.
47. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
48. Bianchi S, Bigazzi R, Quinones G, et al. Insulin resistance in microalbuminuric hypertension: sites and mechanisms. Hypertension. 1995;57:1803-1817.
49. Jacob G, Costa F, Biaggioni I. Spectrum of autonomic cardiovascular neuropathy in diabetes. Diabetes Care. 2003;26:2174-2180.
50. Weinberger MH. Salt sensitivity in human hypertension. Endo Res. 1991;18:67-71.
51. Luft FC, Miller JZ, Grim CE, et al. Salt-sensitivity and resistance of blood pressure: age and race as factors in physiologic responses. Hypertension. 1991;17:1102-1108.
52. Pickering TG, Kario K. Nocturnal non-dipping: what does it augur? Curr Opin Nephrol Hypertens. 2001;10:611-616.
53. Nielsen FS, Hansen HP, Jacobsen P, et al. Increased sympathetic activity during sleep and nocturnal hypertension in type 2 diabetic patients with diabetic nephropathy. Diabet Med. 1999;16:555-562.
54. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20: 2183-2189.
55. Sowers JR, Reed J. Clinical advisory: treatment of hypertension and diabetes. J Clin Hypertens. 2000;2:132-133.
56. Sowers JR, Farrow SL. Treatment of elderly hypertensive patients with diabetes, renal diseases and coronary heart disease. Am J Geriatr Cardiol. 1996;5:57-70.
57. Sowers JR, Lester M. Diabetes and cardiovascular disease. Diabetes Care. 1999;22(suppl 3):C14-C20.
58. Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention Phase 1. JAMA. 1992;267:1213-1220.
59. Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial (HPT): 3-year effects of dietary changes in blood pressure. Arch Intern Med. 1990;150:153-162.
60. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, Phase II. Arch Intern Med. 1997;157:657-667.
61. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544-549.
62. Wassertheil-Smoller S, Blaufox D, Oberman AS, et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992;152:131-136.
63. Sacks FM, Svetkey LP, Vollmer WM, et al. The DASH-Sodium Collaborative Research Group. Effects on BLOOD PRESSURE of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med. 2001;344:3-10.
64. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
65. Hu G, Barengo NC, Tuomilehto J, et al. Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension. 2004;43:25-30.
66. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493-503.
67. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2571.
68. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with Hypertension and Diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
69. International Society of Hypertension Writing Group. World Health Organization, 2003 World Health Organization (WHO)/International society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
70. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
71. Adler AI, Stratton IM, Neil HAW, et al. ., on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000; 321:412-419.
72. Curb JD, Pressel SL, Cutler J, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
73. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. ., for the Systolic Hypertension in Europe Trial investigators. Effect of calcium-channel blockage in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
74. Wong ND, Pio JR, Franklin SS, et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003;91:1421-1426.
75. McFarlane S, Gizycki HV, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care. 2002;25:718-723.
76. Yosuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
77. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
78. Hansson L, Lindholm LH, Niskanen L, et al. ., for the Captopril Prevention Project (CAPPP) study group: effect of angiotensin-converting-enzyme inhibition compared with conventional morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
79. Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
80. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens. 1994;7:84S-092S.
81. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
82. Ravid M, Archmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus; a 7-year follow-up study. Arch Intern Med. 1996; 156:286-289.
83. Bakris GL, Smith AC, Richardson DJ, et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomized, multi-center pilot study. J Hum Hypertens. 2002;16:185-191.
84. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685-693.
85. Deedwania PC. Hypertension and diabetes: new therapeutic options. Arch Intern Med. 2000;160:1585-1594.
86. Larochelle P, Clack JM, Marbury TC, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol. 1997;80:1613-1615.
87. Lindholm LH, Ibsen H, Dahlof B, et al. ., for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
88. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-2110.
89. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
90. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2001;349:1893-1906.
91. Bakris GL, Weir MR, Shanifar S, et al. ., for the RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163:1555-1565.
92. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
93. Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of rennin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
94. Ferrari P, Marti HP, Pfister M, et al. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 2002;20:125-130.
95. Lithell H, Hansson L, Skoog I, et al. ., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
96. Pfeffer MA, Swedberg K, Granger CB, et al. ., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-766.
97. Julius S, Kjeldsen SE, Weber M, et al. ., for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
98. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
99. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
100. Bakris GL, Sowers JR. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk? Hypertension. 2004;43:941-942.
101. Black HR, Elliot WJ, Neaton JD, et al. Baseline characteristics and early BLOOD PRESSURE control in the CONVINCE Trial. Hypertension. 2001;37:12-18.
102. American Diabetes Association. Hypertension Management in Adults With Diabetes: clinical practice recommendations 2004. Diabetes Care. 2004;27(suppl 1):S65-67.
103. Koyama Y, Kodama K, Suziki M, et al. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens. 2002;15:927-931.
104. Zanella MT, Kohlmann O Jr, Ribero AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001;38:705-708.
105. Black HR, Elliott WJ, Grandits G, et al. ., for the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
106. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. ., for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
107. Birkenhager WH, Staessen JA, Gasowski J, et al. Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol. 2000; 13:232-237.
108. Bakris GL, Smith AC, Richardson DJ, et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomized, multi-centre pilot study. J Hum Hypertens. 2002;16:185-191.
109. Higashi Y, Itabe H, Fukase H, et al. Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum. J Biol Chem. 2003;278:21450-21458.
110. Mykkanen L, Kuusisto J, Pyorala K, et al. Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive patients. J Hypertens. 1994;12:1425-1432.
111. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
112. Jacob S, Rett K, Wickelmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489-494.
113. Jacob S, Balletshofer B, Henriksen EJ, et al. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press. 1999;8:261-268.
114. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomised, controlled trial. Ann Intern Med. 1997;126:955-959.
115. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicenter, randomized study. Int J Clin Pract. 1999;53:519-520.
116. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385-1390.
117. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): a randomized controlled trial. Lancet. 2003;362:7-13.
118. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patients with hypertension. Am J Med. 1996;101:33S-46S.
119. Khoury AF, Kaplan NM. Alpha-blocker therapy of hypertension: an unfulfilled promise. JAMA. 1991;17:266:394-398.
120. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921.
121. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the International Society for Heart and Lung Transplantation endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2001;38:2101.
122. Leclercq-Meyer V, Herchuelz A, Valverde I, et al. Mode of action of clonidine upon islet function: dissociated effects upon the time course and magnitude of insulin release. Diabetes. 1980;29:193-200.
123. US Department of Health and Human Services National Heart Lung and Blood Institute. National High Blood Pressure Education Program. Available at: http://www.nhlbi.nih.gov/about/nhbpep/index.htm.
124. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
125. Weber MA. Treating hypertension in the elderly. Am J Geriatr Cardiol. 2003;12:361-362.
126. David CJ, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
127. Hanson L, Llindholm LH, Ekbom T, et al. ., for the STOP-Hypertension-2 Study Group. Randomized trial of old and new antihypertensives: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet. 1999;354:1751.
128. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States. JAMA. 2003;290:199.
129. Berenson GS, Voors AW, Webber LS, et al. Racial differences of parameters associated with blood pressure levels in children: the Bogalusa Heart Study. Metabolism. 1979;28:1218-1228.
130. Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, NIDDM and ESRD. Am J Kidney Dis. 1995;25:350.
131. Sowers JR, Epstein M, Frohlich E. Diabetes, hypertension and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
132. Rahman M, Douglas JG, Wright JT Jr. Pathophysiology and treatment implications of hypertension in the African American population. Endocrinol Metab Clin North Am. 1997;26:125-144.
133. Chapman JN, Mayet J, Chang CL, et al. Ethnic differences in identification of left ventricular hypertrophy in the hypertensive patient. Am J Hypertens. 1999;12:437-442.
134. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1993;329:600-606.
135. Grubbs AL. A review of endothelin and hypertension in African American individuals. Ethnicity and Disease. 2001;11:741-748.
136. Berman S, Key BO, Kirk KA, et al. Kidney disease in the first degree relatives of African Americans with hypertensive end stage renal disease. Am J Kidney Dis. 1996;27:341.
137. Brancate F, Whilli JC, Whelton P, et al. The excess incidence of diabetic end stage renal disease among blacks. A population based study of potential explanatory factors. JAMA. 1992;268:3079-3084.
138. Brancat FL, Kao WH, Folsom AR, et al. Incidence of type 2 diabetes in African Americans and white adults in the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253-2259.
139. Feldman HI, Klag MJ, Chiapella AP, et al. End stage renal disease in US minority groups. Am J Kidney Dis. 1992;19:397.
140. Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc. 2002;94(suppl):7S-15S.
141. Appel LJ, Moore TJ, Obarzanek E, et al., for the DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.
142. Lopes AA. Hypertension in black people: pathophysiology and therapeutic aspects. J Hum Hypertens. 2002;16(suppl 1):S11-12.
143. Weir MR, Gray JM, Paster R, et al. Differing mechanisms of action of angiotensin converting enzyme inhibition in black and white hypertensive patients. Hypertension. 1995;25:124.
144. Wright JT Jr, Bakris G, Green T, et al. The effect of blood pressure lowering drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA. 2002;28:2421-2431.
145. Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-1686.
146. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretics. JAMA. 2002;288:2981-2997.
147. Jackson JH IV, Bramley TJ. Determinants of uncontrolled hypertension African American population. Ethnicity and Disease. 2002;12:53-57.
148. Ramirez AG. Hypertension in Hispanic Americans: overview of the population. Public Health Rep. 1996;111(suppl 2):25-26.
149. Shetterly SM, Rewers M, Hamman RF, et al. Patterns and predictors of hypertension incidence among Hispanic and non Hispanic whites: the San Luis Valley Diabetes Study. J Hypertens. 1994;12:1095-1102.
150. Haffner SM, Mitchell BD, Stern MP. Decreased prevalence of hypertension in Mexican Americans. Hypertension. 1990;16:225-232.
151. Brown DW, Giles WH, Greenland KJ, et al. Association of hyperinsulinemia and hypertension independent of body mass among white black and Mexican American adults without diabetes. Ethnicity and Disease. 2002;12:213-220.
152. Rhoades ER. American Indians and Alaska Natives. Overview of the population. Public Health Rep. 1996;111(suppl 2):49-50.
153. De Courten MP, Pettitt DJ, Knowler WC. Hypertension in Pima Indians: prevalence and predictors. Public Health Rep. 1996;111(suppl 2):40-43.
154. Howard BV, Lee ET, Yeh JL, et al. Hypertension in adult American Indians. The Strong Heart Study. Hypertension. 1996;28:256-264.
155. Jamerson K, DeQuartro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101:22S-32S.
156. McNeely MJ, Boyko EJ. Type 2 diabetes prevalence in Asian Americans. Diabetes Care. 2004;27:66-69.
157. Duerenberg P, Deurenbert-Yap M, Guncci S. South Asians are different from Caucasians and from each other in their body mass index/body fat percent relationships. Obes Rev. 2002;3:141-146.
158. Fujimoto WY, Bergstrom RW, Boyko EJ, et al. Susceptibility to development of central adiposity among populations. Obesity Res. 1995;3(suppl 2):179S-186S.
159. Park YW, Allison DB, Heymsfield SB, et al. Large amounts of visceral adipose tissue in Asian Americans. Obey Res. 2001;9:381-387.
160. Shin CS, Lee HK, Koh CS, et al. Risk factors for the development of NIDDM in Yonchon County Korea. Diabetes Care. 1997;20:1842-1846.
161. Thompson D, Edelsberg J, Colditz GA, et al. Lifetime health and economic consequences of obesity. Arch Intern Med. 1999;159:2117.
162. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867.
163. Williams B. Insulin resistance: the shape of things to come. Lancet. 1994;344:521.
164. Hall JE. Renal and cardiovascular mechanisms of obesity. Hypertension. 1994;23:381.
165. Phillips BG, Narkiewicz K, Pesek CA, et al. Effects of obstructive sleep apnea on endothelin and blood pressure. J Hypertens. 1999;17:61.
166. Reisin E, Weir MR, Falkner B, et al. Treatment in Obese Patients with Hypertension (TROPHY) Study Group. Lisinopril vs hydrochlorothiazide in obese hypertensive patients. Hypertension. 1997;30:140.
167. Davis BR, Oberman A, Blaufox MD, et al. Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. Hypertension. 1992;19:393.
168. Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300:902.
169. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003;21:1761-1769.
170. National High Blood Pressure Education Program. Report of the National High Blood Pressure Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.